RT Journal Article SR Electronic T1 90Y Radioembolization of Colorectal Hepatic Metastases Using Glass Microspheres: Safety and Survival Outcomes from a 531-Patient Multicenter Study JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 665 OP 671 DO 10.2967/jnumed.115.166082 VO 57 IS 5 A1 Ryan Hickey A1 Robert J. Lewandowski A1 Totianna Prudhomme A1 Eduardo Ehrenwald A1 Brian Baigorri A1 Jeffrey Critchfield A1 Joseph Kallini A1 Ahmed Gabr A1 Boris Gorodetski A1 Jean-Francois Geschwind A1 Andrea Abbott A1 Ravi Shridhar A1 Sarah B. White A1 William S. Rilling A1 Brendan Boyer A1 Shannon Kauffman A1 Sharon Kwan A1 Siddarth A. Padia A1 Vanessa L. Gates A1 Mary Mulcahy A1 Sheetal Kircher A1 Halla Nimeiri A1 Al B. Benson A1 Riad Salem YR 2016 UL http://jnm.snmjournals.org/content/57/5/665.abstract AB Hepatic metastases of colorectal carcinoma are a leading cause of cancer-related mortality. Most colorectal liver metastases become refractory to chemotherapy and biologic agents, at which point the median overall survival declines to 4–5 mo. Radioembolization with 90Y has been used in the salvage setting with favorable outcomes. This study reports the survival and safety outcomes of 531 patients treated with glass-based 90Y microspheres at 8 institutions, making it the largest 90Y study for patients with colorectal liver metastases. Methods: Data were retrospectively compiled from 8 institutions for all 90Y glass microsphere treatments for colorectal liver metastases. Exposure to chemotherapeutic or biologic agents, prior liver therapies, biochemical parameters before and after treatment, radiation dosimetry, and complications were recorded. Uni- and multivariate analyses for predictors of survival were performed. Survival outcomes and clinical or biochemical adverse events were recorded. Results: In total, 531 patients received 90Y radioembolization for colorectal liver metastases. The most common clinical adverse events were fatigue (55%), abdominal pain (34%), and nausea (19%). Grade 3 or 4 hyperbilirubinemia occurred in 13% of patients at any time. The median overall survival from the first 90Y treatment was 10.6 mo (95% confidence interval, 8.8–12.4). Performance status, no more than 25% tumor burden, no extrahepatic metastases, albumin greater than 3 g/dL, and receipt of no more than 2 chemotherapeutic agents independently predicted better survival outcomes. Conclusion: This multiinstitutional review of a large cohort of patients with colorectal liver metastases treated with 90Y radioembolization using glass microspheres has demonstrated promising survival outcomes with low toxicity and low side effects. The outcomes were reproducible and consistent with prior reports of radioembolization.